NASDAQ:AGLE

Aeglea BioTherapeutics Earning Date

USA |NASDAQ |USD

AGLE Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 3, 2021 Sep 2021 $-0.28 $-0.10 $-0.29
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 3, 2021 Sep 2021 $4.05M $13.70K $0.00

Aeglea Biotherapeutics's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.

AGLE Earnings Date & History Chart

AGLE Earnings & Revenue Forecast

AGLE Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 7 $-0.31 $-0.36 $-0.28
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 8 $-0.98 $-1.05 $-0.85
Dec 2022 8 $-0.96 $-1.57 $0.56

AGLE Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-0.31 $-0.33 $-0.29
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 1 / 0 $-0.98 $-1.02 $-1.03
Dec 2022 0 / 0 $-1.02 $-0.94 $-0.92

AGLE Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 5 $550.00K $0.00 $1.37M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 6 $17.58M $13.70M $23.20M
Dec 2022 5 $7.29M $0.00 $25.90M

AGLE Earnings Date & Revenue History

AGLE Earnings History

|
Show More
Show More

AGLE Revenue History

|
Show More
Show More

Aeglea Biotherapeutics Next Earnings Date & Report

AGLE Next Earnings Date & Report Preview: Sep 2021 (FQ)

AGLE's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 7 analysts, the average EPS estimation for Aeglea Biotherapeutics's next quarterly earnings is $-0.28, with a low EPS estimation of $-0.33, and a high estimation of $-0.17.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.28, the last 2 month trend is $-0.31, and the 3 month trend is $-0.28.

Based on 5 analysts, the average revenue estimation is $4.05M, with a low revenue estimation of $0.00, and a high estimation of $9.50M.

Aeglea Biotherapeutics Previous Earnings Dates & Reports

AGLE Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Aeglea Biotherapeutics's previous earnings date was Aug 5, 2021 for its fiscal quarter ended Jun 30, 2021.

AGLE's earnings per share (EPS) was $-0.10, beating the consensus analysts forecast of $-0.17 by 41.86%.

The EPS was higher than the previous fiscal quarter (Mar 2021) by -64.29%, and higher than the same period a year before (Jun 2020) by -75.00%.

Revenues were $13.70K.

The company reported a net income of $-6.83K.

Free cash flow for the quarter was $-17.93M , compared to $-19.98M last quarter and $-20.74M a year before.

AGLE ended the quarter with $5.29M in total debt, a decrease of -0.60% compared to the previous quarter, and an increase of 7.50% compared to the same quarter a year before.

AGLE Previous Earnings Date & Report Recap: Dec 2020 (FY)

Aeglea Biotherapeutics's previous annual earnings date was Mar 18, 2021 for its fiscal year ended Dec 31, 2020.

AGLE's earnings per share (EPS) was $-1.60, missing the consensus analysts forecast of $-1.50 by 6.67% , and higher than the previous year's EPS (Dec 2019) by -34.69%.

Revenues were $21.84K.

The company reported a net income of $-80.89M.

Aeglea Biotherapeutics reported a free cash flow of $-80.06M for its fiscal year, compared to $-67.18M a year ago.

The company ended the fiscal year with $5.45M in total debt, an increase of 7.60% compared to the previous year.